menu

Interstitial Lung Disease in Scleroderma: Early Recognition and Emerging Therapeutic Options

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Interstitial Lung Disease in Scleroderma: Early Recognition and Emerging Therapeutic Options

Interstitial Lung Disease in Scleroderma: Early Recognition and Emerging Therapeutic Options
RestartResume
Dr. Dinesh Khanna, Director of the Scleroderma Program at the Univ. of Michigan, discusses managing patients with SS-ILD.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    One of the most debilitating complications of Systemic Sclerosis (SS) is interstitial lung disease (ILD), which is the leading cause of death in patient with SS.  Early detection and classification based on declining lung function and determination of the extent and type of lung involvement based on high-resolution computer tomography (HRCT) is critical for diagnosis and management.  Once SS-ILD is diagnosed, there are no clear guidelines for when to initiate treatment, no recommendations for monitoring treatment.  Another major barrier to effective management of the disease, there are serious limitations to current therapies.  

    This activity will clarify the most current evidence to help clinicians manage their patients with SS-ILD, and review emerging options that may change the standard of care of these patients and enhance outcomes.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host
    Shira Johnson, MD
    Loretto Hospital
    Chicago, IL

    Dr. Johnson has nothing to disclose.

    Faculty: 
    Dinesh Khanna, MD, MS
    Frederick G. L Huetwell Professor
    Professor of Medicine
    Director, Scleroderma Program
    The University of Michigan

    Dr. Khanna receives consulting fees from Actelion, Bayer, BMS, BI, Chemomab, Corbus, Covis, Cytori, Eicos, EMD Serono, Genentech/Roche, Gilead, GSK, Pfizer, Sanofi Aventis and UCB Pharma.  He has contracted research with Bayer, BMS, Covis, EMD Serono, Genentech/Roche, GSK, NIH R01R070470 & K24AR063121, Pfizer, Sanofi Aventis, UCB Pharma and he has ownership interest in Eicos.

    Reviewers/Planners/Authors:

    • Carole Drexel, PhD has nothing to disclose.
    • Nick Lombardi has nothing to disclose.
    • Jessica McGrory has nothing to disclose.
    • Ashley Rosenthal has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe current strategies for early detection, diagnosis and risk stratification to guide appropriate treatment of patients with SS-ILD
    • Apply current evidence to determine the appropriate time to start, modify and stop treatment in patients with SS-ILD
    • Summarize current and ongoing clinical trials on emerging agents for SS-ILD management and discuss their place in therapy based on improved understanding of SS-ILD
  • Target Audience

    This activity is designed to meet the educational needs of Pulmonologists, Rheumatologists and clinicians who manage patients with Interstitial Lung Disease.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

  • Commercial Support

    This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.